Publication:
Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2e) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study

Simple item page
dc.conference.dateMAY 03-05, 2022
dc.conference.titleEuropean-Society-for-Medical-Oncology (ESMO) Breast Cancer Congress
dc.contributor.authorCardoso, F.
dc.contributor.authorJuric, D.
dc.contributor.authorLerebours, F.
dc.contributor.authorKrop, I.
dc.contributor.authorBorrego, M. Ruiz
dc.contributor.authorNeven, P.
dc.contributor.authorPark, Y. H.
dc.contributor.authorYardley, D.
dc.contributor.authorJhaveri, K.
dc.contributor.authorArce, C.
dc.contributor.authorGu, E.
dc.contributor.authorAkdere, M.
dc.contributor.authorRugo, H. S.
dc.contributor.authoraffiliation[Cardoso, F.] Champalimaud Fdn Champalimaud Clin Ctr, Breast Unit, Lisbon, Portugal
dc.contributor.authoraffiliation[Juric, D.] Massachusetts Gen Hosp, Ctr Canc, Dept Oncol Hematol, Boston, MA USA
dc.contributor.authoraffiliation[Juric, D.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA
dc.contributor.authoraffiliation[Lerebours, F.] Inst Curie, Dept Med Oncol, St Cloud, France
dc.contributor.authoraffiliation[Krop, I.] Dana Farber Canc Inst, Div Breast Oncol, Susan F Smith Ctr Womens Canc, Boston, MA 02115 USA
dc.contributor.authoraffiliation[Borrego, M. Ruiz] Hosp Virgen Rocio de Sevilla, Dept Oncol, Seville, Spain
dc.contributor.authoraffiliation[Neven, P.] Univ Hosp, Dept Oncol, Leuven, Belgium
dc.contributor.authoraffiliation[Park, Y. H.] Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr, Seoul, South Korea
dc.contributor.authoraffiliation[Yardley, D.] Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA
dc.contributor.authoraffiliation[Yardley, D.] Tennessee Oncol, Nashville, TN USA
dc.contributor.authoraffiliation[Jhaveri, K.] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, New York, NY USA
dc.contributor.authoraffiliation[Arce, C.] Novartis Pharmaceut, Oncol Global Med Affairs Clin Operat, E Hanover, NJ USA
dc.contributor.authoraffiliation[Gu, E.] Novartis Inst BioMed Res, Oncol WMA Biostat, Cambridge, MA USA
dc.contributor.authoraffiliation[Akdere, M.] Novartis Pharma AG, Med Affairs Oncol, Basel, Switzerland
dc.contributor.authoraffiliation[Rugo, H. S.] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
dc.date.accessioned2023-05-03T14:40:12Z
dc.date.available2023-05-03T14:40:12Z
dc.date.issued2022-05-05
dc.identifier.doi10.1016/j.annonc.2022.03.194
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753422005737/pdf
dc.identifier.urihttp://hdl.handle.net/10668/21904
dc.identifier.wosID792494100178
dc.issue.number3
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationHospital Universitario Virgen del Rocío
dc.page.numberS206-S207
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleAlpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2e) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number33
dc.wostypeMeeting Abstract
dspace.entity.typePublication

Files

Collections

SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía